You are here

R&D

J&J collaborates with Aldeyra on new drugs for systemic inflammatory diseases

Endpoints

Tue, 02/27/18 - 09:49 am

Aldeyra Therapeutics

inflammatory disease

Bristol losing its I/O talent to the likes of Pfizer, report finds

Biopharma Dive

Sat, 02/24/18 - 10:39 pm

Bristol-Myers Squibb

immuno-oncology

3 Big Drugmakers Boosting Huge R&D Budgets

Motley Fool

Sat, 02/24/18 - 11:23 am

Bristol-Myers Squibb

Bristol-Myers axes 107 more staffers as it completes an R&D overhaul

Endpoints

Thu, 02/22/18 - 11:10 am

Bristol-Myers Squibb

The Deeply Human Core of Roche's $2.1B Tech Acquisition - And Why They Did It

Forbes

Sun, 02/18/18 - 02:54 pm

Flatiron Health

$100B in NIH-funded research played an important role in all 210 new drugs approved over 7 years — study

Endpoints

Tue, 02/13/18 - 09:57 am

drug development

research funding

What’s the trouble with pain? Analysis shows scarce investments, high failure rate for new drugs

Endpoints

Mon, 02/12/18 - 04:42 pm

drug development

Lilly, Livongo team up for real-world diabetes research, aiming for better results in an outcomes-oriented market

Fierce Pharma

Mon, 02/12/18 - 04:31 pm

Research in pharma less and less profitable, economic return as little as 3%

GoinPharma

Sat, 02/10/18 - 09:28 am

The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease

Yahoo/Benzinga

Fri, 02/9/18 - 12:00 am

Alzheimer's disease

No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging

Endpoints

Thu, 02/8/18 - 11:18 am

Gilead Sciences

ABBV to Focus on Advancing Late-Stage Immunology Research in 2018

Market Realist

Thu, 02/8/18 - 11:17 am

GSK focuses on R&D with tough year ahead

Biopharma Dive

Wed, 02/7/18 - 10:24 pm

After FDA setback, Bellicum bolsters R&D team with ex-Genentech executive

Fierce Biotech

Tue, 02/6/18 - 09:51 am

Dramatic statement by Teva executive: “Teva must decrease to 2003 size”

GoinPharma

Mon, 02/5/18 - 08:25 am

Teva Pharmaceutical

Merck R&D chief Roger Perlmutter offers some heavyweight R&D glam to a little upstart biotech out to cure Duchenne MD

Endpoints

Tue, 01/30/18 - 09:26 am

Roger Perlmutter

Duchenne Muscular Dystrophy

Exonics Therapeutics

Merck spinout grabs some assets and launches a quest for the Holy Grail in antibiotics R&D

Endpoints

Mon, 01/29/18 - 10:30 am

Biotech CEOs: Working with CROs is challenging

Biopharma Dive

Tue, 01/23/18 - 09:19 am

Fast-growing Gilead buys an R&D campus for $135M

Endpoints

Mon, 01/22/18 - 05:39 pm

Gilead Sciences

Big Pharma invests in research for new antibiotics ($2bn)

GoinPharma

Sun, 01/21/18 - 09:05 pm

Pages